1. Home
  2. ETNB vs RES Comparison

ETNB vs RES Comparison

Compare ETNB & RES Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ETNB
  • RES
  • Stock Information
  • Founded
  • ETNB 2018
  • RES 1984
  • Country
  • ETNB United States
  • RES United States
  • Employees
  • ETNB N/A
  • RES N/A
  • Industry
  • ETNB Biotechnology: Pharmaceutical Preparations
  • RES Oilfield Services/Equipment
  • Sector
  • ETNB Health Care
  • RES Energy
  • Exchange
  • ETNB Nasdaq
  • RES Nasdaq
  • Market Cap
  • ETNB 1.0B
  • RES 1.1B
  • IPO Year
  • ETNB 2019
  • RES N/A
  • Fundamental
  • Price
  • ETNB $10.05
  • RES $4.53
  • Analyst Decision
  • ETNB Strong Buy
  • RES Hold
  • Analyst Count
  • ETNB 8
  • RES 3
  • Target Price
  • ETNB $26.43
  • RES $5.75
  • AVG Volume (30 Days)
  • ETNB 2.1M
  • RES 1.0M
  • Earning Date
  • ETNB 05-01-2025
  • RES 07-24-2025
  • Dividend Yield
  • ETNB N/A
  • RES 3.60%
  • EPS Growth
  • ETNB N/A
  • RES N/A
  • EPS
  • ETNB N/A
  • RES 0.35
  • Revenue
  • ETNB N/A
  • RES $1,370,043,000.00
  • Revenue This Year
  • ETNB N/A
  • RES $16.82
  • Revenue Next Year
  • ETNB N/A
  • RES $11.80
  • P/E Ratio
  • ETNB N/A
  • RES $12.57
  • Revenue Growth
  • ETNB N/A
  • RES N/A
  • 52 Week Low
  • ETNB $4.16
  • RES $4.10
  • 52 Week High
  • ETNB $11.84
  • RES $7.54
  • Technical
  • Relative Strength Index (RSI)
  • ETNB 68.44
  • RES 38.24
  • Support Level
  • ETNB $8.94
  • RES $4.39
  • Resistance Level
  • ETNB $9.70
  • RES $4.62
  • Average True Range (ATR)
  • ETNB 0.73
  • RES 0.13
  • MACD
  • ETNB 0.14
  • RES -0.02
  • Stochastic Oscillator
  • ETNB 93.78
  • RES 12.88

About ETNB 89bio Inc.

89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).

About RES RPC Inc.

RPC Inc is an oilfield services company. It provides specialized oilfield services and equipment to independent and oil and gas companies engaged in the exploration, production, and development of oil and gas properties throughout the United States. The company's operating segment includes Technical Services and Support Services. It generates maximum revenue from the Technical Services segment. Technical Services segment nclude RPC's oil and gas services that utilize people and equipment to perform value-added completion, production and maintenance services directly to a customer's well. Support Services segment consists of drill pipe and related tools, pipe handling, pipe inspection and storage services, and oilfield training and consulting services.

Share on Social Networks: